SCHEMBL13635655

SCHEMBL13635655

Fc1cccc2c1OCC2

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.52
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
KCNH2 Q12809 1/20 0.35
NR3C1 P04150 1/20 0.35
DRD2 P14416 2/20 0.35
DRD3 P35462 1/20 0.35
RORC P51449 1/20 0.35
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
ACHE P22303 1/20 0.34
HRH1 P35367 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CYP19A1 P11511 1/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29791283 1.00 PARP1 (0.52) PARP1HTR1AADRA2ASLC6A2SLC6A4
SCHEMBL1812982 0.88 ACHE (0.42) PARP1HTR1AADRA2ADRD2DRD3
SCHEMBL4596938 0.83 PARP1 (0.45) PARP1HTR1ASLC6A2SLC6A4KCNH2
SCHEMBL27896035 0.79 KCNH2 (0.43) PARP1SLC6A2SLC6A4KCNH2HTR2A
SCHEMBL257506 0.78 PARP1 (0.52) PARP1ADRA2ASLC6A2SLC6A4KCNH2
SCHEMBL22474525 0.76 DRD2 (0.38) PARP1HTR1ANR3C1DRD2DRD3
SCHEMBL24217712 0.75 ACHE (0.33) PARP1ADRA2AACHE
SCHEMBL20565286 0.75 SSTR4 (0.47)
SCHEMBL13651166 0.74 PARP1 (0.52) PARP1HTR1ASLC6A2SLC6A4KCNH2
SCHEMBL293877 0.74 PARP1 (0.52) PARP1HTR1ASLC6A2SLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 US disclosed
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2024-08-08 US disclosed
US-20240083869-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2024-03-14 US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 US disclosed
CN-117242060-A Isoindolinone compounds 蒙特罗萨医疗公司 2023-12-15 CN disclosed
EP-4278014-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 EP disclosed
EP-4277901-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 EP disclosed
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-11-16 US disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed
EP-2802326-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-04-18 EP disclosed
CN-105026392-B 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof 四川海思科制药有限公司 2017-05-10 CN disclosed
CN-104395312-B The Spirocyclic derivatives of 4,5-dihydro-pyrazolo [3,4-c] pyridin-2-ones, its preparation method and application SICHUAN HAISCO PHARMACEUTICAL CO.,LTD. (CN) 2016-04-27 CN disclosed
CN-105026392-A 4,5-dihydro-pyrazolo [3, 4-c] pyrid-2-ones, preparation method and application thereof SICHUAN HAISCO PHARMACEUTICAL CO LTD 2015-11-04 CN disclosed
WO-2014202027-A1 SPIROCYCLIC DERIVATIVE OF 4,5-DIHYDROPYRAZOLO[3,4-C]PYRIDINE-2-ONE, PREPARATION METHOD AND USE THEREOF 四川海思科制药有限公司 (CN) 2014-12-24 WO disclosed
WO-2014169845-A2 4,5-DIHYDRO-PYRAZOLO [3, 4-C] PYRID-2-ONES, PREPARATION METHOD AND APPLICATION THEREOF 四川海思科制药有限公司 (CN) 2014-10-23 WO disclosed
WO-2014169845-A2 4,5-DIHYDRO-PYRAZOLO [3, 4-C] PYRID-2-ONES, PREPARATION METHOD AND APPLICATION THEREOF 四川海思科制药有限公司 (CN) 2014-10-23 WO disclosed
CN-104109165-A 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-one derivatives, and preparation method and application thereof SICHUAN HAISCO PHARMACEUTICAL CO LTD 2014-10-22 CN disclosed
EP-1409441-B1 INDANE COMPOUNDS WITH NEGATIVE DIELECTRIC ANISOTROPY MERCK PATENT GMBH (DE) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 PARP1 4554/4885HTR1A 2526/4885ADRA2A 364/4885
US-20240083869-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 PARP1 4554/4885HTR1A 2526/4885ADRA2A 364/4885
US-11912682-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 PARP1 4554/4885HTR1A 2526/4885ADRA2A 364/4885
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MYC, MYCBP, GSPT1 PARP1 225/4885HTR1A 3479/4885ADRA2A 4645/4885
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF BTK, WEE2, WEE1 PARP1 4315/4885HTR1A 1261/4885ADRA2A 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.